Formulation and specifications: Tablets: 100 mg, 150 mgIndications: For adult patients with metastatic desmoplastic-resistant prostate cancer who carry germline or somatic BRCA mutations and who have failed prior therapy, including…
Formulation and specifications: Injection: 80mg (2ml)/bottle, 240mg (6ml)/bottleIndications: For locally advanced or metastatic uroepithelial carcinoma that has failed platinum-containing chemotherapy including neoadjuvant or adjuvant chemotherapy progressing within 12 months.Key points…
Formulation and specifications: Injection: 100mg (10ml)/vialIndications: Indicated for the treatment of locally advanced or metastatic uroepithelial carcinoma that has failed platinum-containing chemotherapy including neoadjuvant or adjuvant chemotherapy within 12 months…
Formulation and specifications: Injection: 100mg (4ml)/bottleIndications:1. Pabrolizumab in combination with axitinib is indicated for the first-line treatment of advanced renal clear cell carcinoma.2. For the treatment of advanced uroepithelial carcinoma…
Formulation and specifications: Injection: 40mg (4ml)/bottle, 100mg (10ml)/bottleIndications: This product in combination with Ipilimumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma with an International…
Formulation and Specifications: Capsules: 4mg, 10mgIndications: Combined with everolimus for the treatment of advanced renal cell carcinoma (RCC) that has failed or progressed on prior antiangiogenic therapy.Rational Dosing Points:1. The…
Formulation and Specifications: Tablets: 200 mgIndications: This product is indicated for the first-line treatment of patients with advanced RCC and for the treatment of patients with advanced RCC who have…
Formulation and specifications: Tablets: 1mg, 5mgIndications:1. For adult patients with progressive RCC who have failed prior treatment with a tyrosine kinase inhibitor or cytokine.2. In combination with pablizumab for the…
Formulation and specifications: Capsules: 12.5mg, 25mg, 37.5mg, 50mgIndications: Advanced kidney cancer.Key points for rational drug use:1. The recommended dose is 50 mg orally once daily for 4 weeks and 2…
Formulation and specifications: Tablets: 200mgIndications: Advanced kidney cancer.Key points for rational drug use:1. CYP3A4 inducers in combination with sorafenib may reduce the drug concentration of sorafenib, and based on current…